Medivation jumps on AFFIRM data

Medivation Inc. (NASDAQ:MDVN) jumped $12.16 (22%) to $67.57 on Wednesday after reporting additional data from the Phase III AFFIRM trial of MDV3100 to treat castration-resistant prostate cancer (CRPC)...